What the law sources say about MOTS-c now.
A licensed provider decides on each MOTS-c request. The FDA entry still carries safety concerns.
What the Past FDA Meeting Notice Proves
Animal and dish tests measured sugar use, weight, and strength. They didn't prove MOTS-c safe or useful as medicine.
FDA hasn't approved MOTS-c as medicine or as a dietary supplement. A clinician licensed in the U.S. checks MOTS-c prescription requests made to Promise Peptides (mypromise.com).
FDA set a public review for July 23–24, 2026. The meeting took place; a discussion does not give a medicine FDA approval [18].
The meeting notice alone did not change pharmacy law. Outside experts advise FDA; the agency makes its own listing decision [16].
A licensed provider reviews each request and decides; not everyone qualifies. Access is limited to U.S. patients and varies by state and treatment. Compounded medications are not FDA-approved.
What the Cited Law Allows a Pharmacy to Do
MOTS-c is a small protein made from sixteen linked parts. MOTS-c has no FDA approval to treat illness.
Research supplies are separate from prescription medication. There is no approved human use, product, or dose.
For one-patient pharmacy work, the ingredient must pass at least one of three tests [16]. It may sit on FDA's list, meet an official book's quality test, or appear in an approved drug.
FDA lists MOTS-c among ingredients whose nominations were withdrawn, with the safety concerns still present [17]. FDA may review an ingredient in public when no test applies [16].
MOTS-c was placed on a meeting agenda for that review [18]. An agenda spot doesn't add MOTS-c to the allowed list.
MOTS-c was previously in Category 2 [17]. A withdrawn nomination does not put it in Category 1 or establish permission to compound.
Plain answer: prescribing access and FDA ingredient rules are separate questions. A prescription does not settle whether an ingredient may be compounded.
What the FDA Meeting Was Asked to Weigh
The FDA paper put MOTS-c on its July 23–24, 2026 meeting agenda [18]. The agenda asked the panel to weigh adding MOTS-c to the pharmacy ingredient list.
The paper names plain MOTS-c and an acetate form. Acetate means part of acetic acid is paired with MOTS-c to form a salt.
The notice doesn't say the acetate form is safer or works better. It also gives that form no different legal standing.
The paper also names BPC-157, TB-500, and KPV, three other lab compounds [18]. Their presence only shows that several ingredients were up for discussion.
The outside panel could discuss the facts, but FDA makes the later choice [16]. A meeting or panel vote would only give FDA advice.
Such advice does not add MOTS-c to FDA's ingredient list. Any lasting change needs a separate FDA step [16].
FDA now records MOTS-c under nominations that were withdrawn [17]. The safety concerns remain; this is not an FDA decision to permit compounding.
What Two Parts of Pharmacy Law Mean
Section 503A labels medicine made for one named patient [16]. A valid prescription is usually required.
Section 503B covers registered sites producing medicine in larger batches [16]. FDA registers and inspects those sites.
Both parts of law control raw drug ingredients, not finished medicine. Each ingredient must pass any one of three legal tests [16].
A pharmacy can't use a lab chemical merely because a prescriber asks. The ingredient rule still comes first.
Category 2 is FDA's label for ingredients with serious safety concerns. FDA's interim 503A policy does not give that group the same protection from enforcement as Category 1 [17].
MOTS-c appears in the separate table of withdrawn nominations, with the safety concerns still listed [17]. That table does not place it in Category 1 or establish eligibility for compounding.
Approval of a finished medicine is a separate matter. MOTS-c isn't an FDA-approved drug [16].
What the Word Supplement Cannot Change
MOTS-c isn't a dietary supplement or an FDA-approved drug [16]. Prescription access does not make it a dietary supplement.
Supplement rules cover vitamins, minerals, herbs, and similar products. Those rules don't turn MOTS-c into a lawful supplement.
Neither the supplement label nor approved-drug label fits MOTS-c. Any pharmacy use would still have to pass the ingredient rules [16].
A bottle or sales page may use the word supplement. Marketing words can't change what the law says.
Calling MOTS-c a supplement doesn't make it one. It also doesn't prove the product is safe.
What a Pharmacy Must Check Before Making Medicine
Medicine made by a pharmacy begins with a licensed prescriber. The prescriber checks one person and may write a valid prescription [16].
After that, a pharmacy may make medicine for that patient. A registered site may make bigger batches under FDA checks [16].
The first visit may happen by phone or video. A remote visit still needs a proper health review, and may end without a prescription [16].
The prescriber needs your health history and current medicines. A quick sales form isn't the same as a health check.
Video doesn't change which ingredients the pharmacy may use. It also can't remove the need for a sound health check [16].
FDA keeps its safety concerns beside the withdrawn MOTS-c entry [17]. A prescription does not remove those concerns or the ingredient rules.
The pharmacy must pass both the patient and ingredient rules. One does not replace the other.
This is general background, not advice about your health or the law. This page doesn't sell, supply, dose, or give use steps.
What the Sport Ban Means for an Athlete
The main U.S. and world sport groups ban MOTS-c at all times. That rule applies to top-level athletes.
Breaking the sport rule can bring a penalty. The ban is separate from FDA pharmacy law.
A clinic's part does not cancel the ban. An athlete needs the current banned list before making a choice.
Pharmacy permission would not erase a sport penalty. The animal results explain why MOTS-c drew interest.